Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Inozyme Pharma (NASDAQ:INZY) and maintained a price target of $23.
August 09, 2023 | 8:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inozyme Pharma's stock rating has been reiterated as 'Buy' by Needham analyst Joseph Stringer, with a maintained price target of $23.
The reiteration of a 'Buy' rating by a reputable analyst like Joseph Stringer is a positive signal for investors. The maintained price target of $23 indicates that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100